Hypoxia biomarkers, oxidative stress, and circulating microparticles in pediatric patients with thalassemia in upper Egypt

Clinical and Applied Thrombosis/Hemostasis

Volumn 20, Issue 5, 2014, Pages 536-545

  Elsayh, Khalid I ^a   Zahran, Asmaa M ^b   El Abaseri, Taghrid B ^c   Mohamed, Amany O ^a   El Metwally, Tarek H ^a  

^a Assiut University Faculty of Medicine   (Egypt)

^b ASSIUT UNIVERSITY   (Egypt)

^c Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

circulating microparticles; fragmented DNA; hypoxia; oxidative stress; thalassemia major

Indexed keywords

BETA3 INTEGRIN; BIOLOGICAL MARKER; DEFEROXAMINE; DNA FRAGMENT; FIBRINOGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTIC ACID; MALONALDEHYDE; PYRUVIC ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VASCULOTROPIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CONTROLLED STUDY; DNA DAMAGE; EGYPT; FEMALE; HUMAN; HYPOXEMIA; HYPOXIA; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; OXIDATIVE STRESS; PRIORITY JOURNAL; STANDARD; THALASSEMIA MAJOR; THROMBOCYTE ACTIVATION; ANOXIA; BLOOD; DNA FRAGMENTATION; METABOLISM; SPLENECTOMY; THALASSEMIA;

ANOXIA; BIOLOGICAL MARKERS; CELL-DERIVED MICROPARTICLES; CHILD; DNA FRAGMENTATION; FEMALE; HUMANS; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; SPLENECTOMY; THALASSEMIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901721053     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612472552     Document Type: Article

References (70)

1. Centis F, Tabellini L, Lucarelli G, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β-thalassemia major. Blood. 2000 ; 96 (10). 3624-3629
2. Sansone G, Masera A, Cantu-Rajnoldi A, Terzoli S. An unclassified case of congenital dyserythropoietic anaemia with a severe neonatal onset. Acta Haematol. 1992 ; 88 (1). 41-45
3. Di Matteo R, Liuzza F, Manicone PF, et al. Bone and maxillofacial abnormalities in thalassemia: a review of the literature. J Biol Regul Homeost Agents. 2008 ; 22 (4). 211-216
4. Aizawa S, Kohdera U, Hiramoto M, et al. Ineffective erythropoiesis in the spleen of a patient with pyruvate kinase deficiency. Am J Hematol. 2003 ; 74 (1). 68-72
5. Ivan M, Kondo K, Yang H, et al. HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001 ; 292 (5516). 464-468
6. Jaakola P, Mole DR, Tian YM, et al. Targeting of HIFα to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001 ; 292 (5516). 468-472
7. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001 ; 294 (5545). 1337-1340
8. Semenza GL.. HIF-1, O (2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell. 2001 ; 107 (1). 1-3
9. Young PP, Hofling AA, Sands MS. VEGF increases engraftment of bone marrow?derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc Natl Acad Sci U S A. 2002 ; 99 (18). 11951-11956
10. Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension. 2004 ; 44 (3). 264-270
11. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006 ; 37 (1). 12-20
12. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma non-transferrin-bound iron in dialysis patients. Eur J Clin Invest. 2002 ; 32 (suppl 1). 42-49
13. Gupta KK, Mishra AK, Tiwari A.. In vitro effect of lycopene on oxidative stress in thalassemia major patients. Int J Pharm Sci. 2012 ; 4 (3). 696-699
14. Gelderman MP, Simak J. Flow cytometric analysis of cell membrane microparticles. Methods Mol Biol. 2008 ; 484: 79-93
15. Freyssinet JM. Cellular microparticles: what are they bad or good for?. J Thromb Haemost. 2003 ; 1 (7). 1655-1662
16. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction (review). Front Biosci. 2004 ; 9: 1118-1135
17. Wang JM, Hung YJ, Wang Y, et al. Increased circulating CD31+/CD42- microparticles are associated with impaired systemic artery elasticity in healthy subjects. Am J Hypertens. 2007 ; 20 (9). 957-964
18. Helal O, Defoort C, Robert S, et al. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr Metab Cardiovasc Dis. 2011 ; 21 (9). 665-671
19. Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol. 2001 ; 54 (5). 356-361
20. Harma M, Harma M, Erel O. Measurement of the total antioxidant response in preeclampsia with a novel automated method. Euro J Obst Gyn Reprod Biol. 2005 ; 118 (1). 47-51
21. Dawn-Linsley M, Ekinci FJ, Ortiz D, Rogers E, Shea TB. Monitoring thiobarbituric acid-reactive substances (TBARs) as an assay for oxidative damage in neuronal cultures and central nervous system. J Neurosci Methods. 2005 ; 141 (2). 219-222
22. Paradones CE, Illera VA, Peckham D, Stunz LL, Ashman RF. Regulation of apoptosis in vitro in mature spleen T cells. J Immunol. 1993 ; 151 (7). 3521-3529
23. van Beers JE, Schaap CLM, Berckmans JR, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009 ; 94 (11). 1513-1519
24. Sommeijer DW, Joop K, Leyte A, Reitsma PH, Ten Cate H. Pravastatin reduces fibrinogen receptor GPIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost. 2005 ; 3 (6). 1168-1171
25. Trappenburg CM, van Schilfgaarde M, Marchetti M, et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica. 2009 ; 94 (7). 911-918
26. Agouni A, Lagrue-Lak-Hal HA, Ducluzeau HP, et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol. 2008 ; 173 (4). 1210-1219
27. Lekawanvijit S, Chattipakorn N. Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can J Cardiol. 2009 ; 25 (4). 213-218
28. Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW. Combined iron chelation therapy. Ann N Y Acad Sci. 2010 ; 1202: 79-86
29. Kennedy A, Kohn M, Lammi A, Clarke S. Iron status and haematological changes in adolescent female in patients with anorexia nervosa. J Paediatr Child Health. 2004 ; 40 (8). 430-432
30. Larade K, Storey KB. Accumulation and translation of ferritin heavy chain transcripts following anoxia exposure in a marine invertebrate. J Exp Biol. 2004 ; 207 (pt 8). 1353-1560
31. Klaus S, Heringlake M, Gliemroth J, Pagel H, Staubach K, Bahlmann L. Biochemical tissue monitoring during hypoxia and reoxygenation. Resuscitation. 2003 ; 56 (3). 299-305
32. Becker PM, Alcasabas A, Yu AY, Semenza GL, Bunton TE. Oxygen-independent upregulation of vascular endothelial growth factor and vascular barrier dysfunction during ventilated pulmonary ischemia in isolated ferret lungs. Am J Respir Cell Mol Biol. 2000 ; 22 (3). 272-279
33. Trollmann R, Amann K, Schoof E, et al. Hypoxia activates the human placental vascular endothelial growth factor system in vitro and in vivo: up-regulation of vascular endothelial growth factor in clinically relevant hypoxic ischemia in birth asphyxia. Am J Obstet Gynecol. 2003 ; 188 (2). 517-523
34. Izraeli S, Ben-Sira L, Harell D, Naor N, Ballin A, Davidson S. Lactic acid as a predictor for erythrocyte transfusion in healthy preterm infants with anemia of prematurity. J Pediatr. 1993 ; 122 (4). 629-631
35. Frey B, Losa M. The value of capillary whole blood lactate for blood transfusion requirements in anaemia of prematurity. Intensive Care Med. 2001 ; 27 (1). 222-227
36. Dunst J, Becker A, Lautenschläger C, et al. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol. 2002 ; 178 (8). 436-444
37. Solovey A, Gui L, Ramakrihnan S, Steinberg MH, Hebbel RP. Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood. 1999 ; 93 (11). 3824-3830
38. Butthep P, Rummavas S, Wisdpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratveg A. Increased circulating endothelial cells, vascular endothelial growth factor and tumor necroses factor in thalassemia. Am J Hematol. 2002 ; 70 (2). 100-106
39. Morris CR, Kuypers FA, Kato GJ, et al. Hemolysis associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 2005 ; 1054: 481-485
40. El-Gezawy EM, Elsayh KI, AbdElAziz NHR, Fathy MA, Nasif KA. Pulmonary hypertension in thalassemic children: does endothelial dysfunction play a role?. Alexandria J Ped. 2008 ; 22 (2). 281-288
41. Walter B, Fung E, Killilea W, et al. Oxidative stress and inflammation in iron-overloaded patients with β-thalassaemia or sickle cell disease. Br J Haematol. 2006 ; 135 (2). 254-263
42. Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest. 2002 ; 32 (1). 55-60
43. Fibach E, Rachmilewitz EA. The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia. Ann N Y Acad Sci. 2010 ; 1202: 10-16
44. Kampa M, Nistikaki A, Tsaousis V, Maliaraki N, Notas G, Castanas E. A new automated method for the determination of the total antioxidant capacity (TAC) of human plasma, based on the crocin bleaching assay. BMC Clin Pathol. 2002 ; 2 (1). 3
45. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical action. Clin Biochem. 2004 ; 37 (4). 277-285
46. Ghone RA, Kumbar KM, Suryakar AN, Katkam RV, Joshi NG. Oxidative stress and disturbance in antioxidant balance in beta thalassemia major. Indian J Clin Biochem. 2008 ; 23 (4). 337-340
47. Hamed EA, ElMelegy NT. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Italian J Pediatr. 2010 ; 36: 39
48. Cakmak A, Soker M, Koc A, Aksoy N. Prolidase activity and oxidative status in patients with thalassemia major. J Clin Lab Anal. 2010 ; 24 (1). 6-11
49. Kunwittaya S, Chanarat P, Mundee Y, Mevatee U. Effect of oxidative stress on leukocyte DNA damage in β-thalassemic patients. Siriraj Med J. 2007 ; 59: 242-244
50. Söker M, Koc A, Erel ö, et al. Oxidant-antioxidant system and lymphocyte DNA damage in beta thalassemia children. Poster presented at EHA; 2009 ; 14:
51. Claster S, Wood JC, Noetzli L, et al. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am J Hematol. 2009 ; 84 (6). 344-348
52. Livrea MA, Tesoriere L, Pintaudi AM, et al. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood. 1996 ; 88 (9). 3608-3614
53. Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol. 2006 ; 132 (1). 108-113
54. Meerang M, Nair J, Sirankapracha P, et al. Accumulation of lipid peroxidation-derived DNA lesions in iron-overloaded thalassemic mouse livers: comparison with levels in the lymphocytes of thalassemia patients. Int J Cancer. 2009 ; 15;125 (4). 759-766
55. Morris CR, Kuypers FA, Kato GJ, et al. Hemolysis associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 2005 ; 1054: 481-485
56. Eldor Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002 ; 99 (1). 36-43
57. Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res. 2003 ; 42 (5). 423-438
58. Horstman LL, Jy W, Jimenez JJ, Bidot C, Ahn YS. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med. 2004 ; 53 (4). 210-230
59. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006 ; 36 (2). 104-107
60. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res. 2009 ; 335 (1). 143-151
61. Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost. 2007 ; 97 (3). 425-434
62. Horne MK, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. Br J Haematol. 2006 ; 133 (4). 403-408
63. Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica. 2008 ; 93 (6). 941-942
64. Wun T, Paglieroni T, Rangaswami A, et al. Platelet activation in patients with sickle cell disease. Br J Haematol. 1998 ; 100 (4). 741-749
65. van Beers EJ, Schaap MC, Berckmans RJ, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009 ; 94 (11). 1513-1519
66. Nantakomol D, Palasuwan A, Chaowanathikhom M, Soogarun S, Imwong M. Red cell and platelet derived microparticles are increased in G6PD deficient subjects. Eur J Haematol. 2012 ; 89 (5). 423-429
67. Pattanapanyasat K, Gonwong S, Chaichompoo P, et al. Activated platelet-derived microparticles in thalassaemia. Br J Haematol. 2007 ; 136 (3). 462-471
68. Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003 ; 102 (7). 2678-2683
69. Inauen W, Granger DN, Meininger CJ, Schelling ME, Granger HJ, Kvietys PR. Anoxia-reoxygenation-induced, neutrophil-mediated endothelial cell injury: role of elastase. Am J Physiol. 1990 ; 259 (3 pt 2). 925-931
70. Semenza GL.. Cellular and molecular dissection of reperfusion injury: ROS within and without. Circ Res. 2000 ; 86 (2). 117-118